Skip to main content
. 2016 Dec 20;68(24):2652–2666. doi: 10.1016/j.jacc.2016.09.946

Figure 1.

Figure 1

AAV Delivery

(A) Study design. (B) Immunohistochemistry for enhanced GFP at 1, 2, and 8 weeks following intravenous delivery of AAVGFP. (Original magnification ×4 for upper panel and ×40 for lower panel; scale = 100 μm.) (C) Quantification of GFP in transduced heart lysates using GFP assay. Fluorescence normalized to negative control heart tissue basal fluorescence and total protein concentration. (D) Mortality for each animal group. Group sizes are n = 10, n = 15, n = 15, and n = 11 for sham, MI, MI/AAVGFP, and MI/AAV Ang-(1-9), respectively. (E) Percent survival and cause of mortality. AAV = adeno-associated virus; Ang-(1-9) = angiotensin-(1-9); GFP = green fluorescence protein; MI = myocardial infarction.